Treos Bio

company

About

Treos Bio, Inc. develops precision cancer immunotherapies tailored to patients' genetics.

  • London,England,United Kingdom
  • 1 - 10

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$8M
Industries
Biotechnology,Clinical Trials,Health Care,Health Diagnostics,Therapeutics
Founded date
Jan 1, 2013
Number Of Employee
1 - 10
Operating Status
Active

Treos Bio, Inc. is a computational immunology and immunotherapy company which has developed a proprietary technology to predict in silico likely responders to cancer immunotherapies and to design in silico next generation targeted immunotherapies for a large population of cancer patients.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$8M €25.67M
Treos Bio has raised a total of $8M €25.67M in funding over 2 rounds. Their latest funding was raised on Mar 31, 2021 from a Convertable Note round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 31, 2021 Convertable Note €14M 2 Luminous Ventures
The Future Fund
Detail
Mar 20, 2021 Series A €11.67M 1 Detail
Feb 13, 2017 Series Unknown $8M 1 BXR Partners LLP Detail

Investors

Number of Lead Investors
Number of Investors
3
4
Treos Bio is funded by 4 investors. Luminous Ventures and The Future Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Luminous Ventures Yes Convertable Note
The Future Fund Yes Convertable Note
BXR Partners LLP Yes Series Unknown
Outsized Ventures Series A

Employee Profiles

Number of Employee Profiles
5
Treos Bio has 5 current employee profiles, including Executive John Hautman
Executive
Executive
Executive
Employee